Skip to main content

Table 4 Country and Regional comparison of oncogenic HPV in histologically-confirmed CIN 2, CIN 3 or CIS lesions

From: Type-specific oncogenic human papillomavirus infection in high grade cervical disease in New Zealand

HPV type

New Zealand * (N=356)

Australia†(N=533)

Global regions‡

Sample weighted mean (%)

n

%

(95% CI)

n

%

(95% CI)

Asia

Europe

North America

South/Central America

16

181

50.8

(45.5-56.2)

274

51.4

(47.1-5.7)

33.7

51.5

33.5

37.6

52β

67

18.8

(14.9-23.3)

74§

13.9

(11.1-7.1)

9.5

2.0

4.8

4.7

31

62

17.1

(13.4-21.5)

77

14.4

(11.617.7)

5.4

9.5

13.1

6.0

33

47

13.2

(9.9-17.2)

49

9.2

(6.9-12.0)

5.9

8.1

5.0

5.1

18

43

12.1

(8.9-15.9)

49

9.2

(6.9-12.0)

6.6

6.0

8.3

5.4

58β

40

11.5

(8.4-15.3)

37

6.9

(4.9-9.4)

12.2

3.5

6.8

11.2

51

36

10.1

(7.2-13.7)

61

11.4

(8.9-14.5)

5.1

2.0

3.4

4.0

39

27

7.3

(4.8-10.5)

44

8.3

(6.4-11.3)

1.2

1.4

3.7

2.4

35

18

4.8

(2.8-7.5)

24

4.5

(2.9-6.6)

3.3

2.2

2.8

3.9

45

16

4.5

(2.6-7.2)

23

4.3

(3.1-6.8)

0

1.5

2.3

6.0

59

15

4.2

(2.4-6.9)

26

4.9

(3.2-7.1)

2.3

0

1.9

1.0

56

10

2.8

(1.4-5.1)

28

5.3

(3.5-7.5)

3.6

2.9

8.7

2.1

68β

8

2.2

(1.0-4.4)

12

2.3

(1.2-3.9)

1.1

0.2

2.4

0.5

Any β

342

94.9

(92.1-97)

485

91.0

(88.2-3.3)

78.0

87.3

78.8

77.9

  1. Oncogenic HPV includes infection with either type 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, or 68; CIN cervical intra-epithelial neoplasia; CIS carcinoma in situ.
  2. * Limited to women with histologically-confirmed CIN 2/3. Excludes AIS, glandular dysplasia or cervical cancer. As discussed in the text, the population was ‘enriched’ because all were originally referred with high grade cytology.
  3. † From Stevens et al. (2009).[9].This study included histologically-confirmed CIN 2+, but squamous cell carcinoma constituted only 9 of 533 cases.
  4. ‡ Re-calculated from data in[24](see text). African region had no studies with HPV type-specific measurement in histologically-confirmed high grade disease.
  5. β Statistically significant difference in prevalence between New Zealand and Australia when compared using HPV prevalence in CIN 2 from both studies.
  6. § HPV type 52 detected via Linear Array in the absence of types 33, 35 or 58; or confirmed via an in-house probe designed to detect type 52 within this subgroup of co-infections. Results for type 52 alone not validated for linear array testing.
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us